Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Mefloquine

Generic name
Mefloquine
Brand name
ATC Code
P01BC02

Pharmacokinetics in children

No relevant age-related changes have been observed in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Prophylaxis for malaria
  • Oral
    • ≥ 5 kg
      [1]
      • 5 mg/kg/dose once a week.
      • Duration of treatment:
        • Start 10 days before departure to endemic area (i.e., 10 days and 3 days before departure 1 dose), then once a week until 4 weeks after leaving endemic area.
        • If it is not possible to start 10 days before departure, a loading dose should be
          given: the weekly chemoprophylactic dose will then be taken on 3 consecutive days (day 1, 2
          and 3), taken on day 8 and then weekly
      • Directions for administration:

        The tablets may be broken and suspended in a little water, milk or another drink.

      • Corrresponding to

        5-20 kg: 62,5 mg/dose
        > 20-30 kg: 125 mg/dose
        > 30-45 kg: 187,5 mg/dose
        > 45 kg: 250 mg/dose
Treatment of uncomplicated malaria
  • Oral
    • ≥ 5 kg
      [1]
      • Total treatment dose: 20 - 25 mg/kg/day in 2 - 3 doses. Max: 1.500 mg/day.
      • Duration of treatment:

        1 day

      • Directions for administration:

        The tablets may be broken and suspended in water, milk or another drink.

      • Corresponding to 62,5 mg per 2,5-3 kg bodyweight or 250 mg per 10-12 kg bodyweight.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

GFR ≥10 ml/min/1.73m2: Dose adjustment not required.

GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Mefloquine has a bitter and slightly burning taste. Lariam tablets should be taken whole, preferably after meals, with at least one glass of liquid. For administering to young children and people who are unable to swallow the whole tablet, the tablets may be broken and suspended in a little water, milk or another drink.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Aminoquinolines
P01BA01
P01BA02
Biguanides
P01BB01
Methanolquinolines
P01BC01
Diaminopyrimidines
P01BD01
Artemisinin and derivatives, plain
P01BE03
Artemisinin and derivatives, combinations
P01BF01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Reference

  1. Roche Nederland BV, SPC Lariam (RVG 11154) 22-03-2021, www.geneesmiddeleninformatiebank.nl

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes